A new trading day began on Tuesday, with Citius Pharmaceuticals Inc (NASDAQ: CTXR) stock price down -3.96% from the previous day of trading, before settling in for the closing price of $0.38. CTXR’s price has ranged from $0.34 to $1.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 2.27%. With a float of $168.40 million, this company’s outstanding shares have now reached $180.72 million.
Considering the fact that the conglomerate employs 22 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Citius Pharmaceuticals Inc (CTXR) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Citius Pharmaceuticals Inc is 6.82%, while institutional ownership is 16.89%.
Citius Pharmaceuticals Inc (CTXR) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.07 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.27% per share during the next fiscal year.
Citius Pharmaceuticals Inc (NASDAQ: CTXR) Trading Performance Indicators
Here are Citius Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.06 in one year’s time.
Technical Analysis of Citius Pharmaceuticals Inc (CTXR)
Compared to the last year’s volume of 1.45 million, its volume of 0.73 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 52.43%. Additionally, its Average True Range was 0.04.
During the past 100 days, Citius Pharmaceuticals Inc’s (CTXR) raw stochastic average was set at 4.76%, which indicates a significant decrease from 25.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.84% in the past 14 days, which was lower than the 88.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5084, while its 200-day Moving Average is $0.6805. Nevertheless, the first resistance level for the watch stands at $0.3889 in the near term. At $0.4088, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4228. If the price goes on to break the first support level at $0.3550, it is likely to go to the next support level at $0.3410. Should the price break the second support level, the third support level stands at $0.3211.
Citius Pharmaceuticals Inc (NASDAQ: CTXR) Key Stats
With a market capitalization of 66.69 million, the company has a total of 180,673K Shares Outstanding. Currently, annual sales are 0 K while annual income is -32,540 K. The company’s previous quarter sales were 0 K while its latest quarter income was -10,570 K.
